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lESKYL- A genetically-improved vaccine to contain pseudorabies disease
The vaccine, namely JESKYl, was developed by using a local type of herpesvirus
originally obtained from a disease outbreak In Malaysia. The vaccine is proven to
be useful to contain the disease, namely pseudorabies, that mainly affects swine and
some other mammals. Without vaccination" an outbreak of the disease may cause a se-
vere loss to the livestock industry.
Meanwhile, UPM has successfully developed the vaccine by
using an advance biotechnology approach. The safety and the
effectiveness of the vaccine have been assured following the
removal of genetic factors that responsible for development of
viral disease. In the process, two important genes have been
removed from the virus or inactivated permanently. To ensure
the safety of the genetically improved vaccine, the virus used
has been grown in an appropriate cell culture continuously and
tested in laboratory for more than 5 years. Another important
feature of the vaccine is, disease-bearing animals can be easily
identified and differentiated from any animal vaccinated with
the vaccine. Meaning the vaccine contains two genetic markers that can easily be identified by one of two
common laboratory tests: DNA testing or antibody testing. This approach has enabled anyone with skill-
in-the-art to rapidly identify infected animals. This approach shall help farmers to remove or slaughter
infected animals and finally achieve an endorsement of pseudorabies disease-free livestock farm. Such
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disease-free status has been achieved in certain countries and the recognition is important for export
purposes.
The technology used for the development of the vaccine has been subjected to patent application. Despite
these advantages, as the vaccine will be produced using local resources, the price of the vaccine is ex-
pected to be cheaper that those imports.
Inactivated Oil Adjuvanted Vaccine-TK and gE gene-deleted virus
Meanwhile, commercialisation of the
vaccine is taken care by Malaysian
Vaccines and Pharmaceuticals (MVP)
Sdn Bhd. Commercialisation of vac-
cine is a complex and well-regulated
process, and monitored by a well-
respected authority in Malaysia.
UPMand MVPhave taken an appro-
priate measure to ensure the safety
and efficacy of the vaccine.
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MVP is manufacturing an appropriate amount of the vaccine, using GMP manufacturing facilities, for the
purpose of field trials in animals. The company intended to manufacture two forms of vaccines using live
or killed virus. This strategy is to capture both the existing market for killed-virus vaccine and the growing
demand for the live-virus vaccine. Obviously, based on annual import and number of animal farms, the
current market size of the vaccine in Malaysia is expected to be about RMl mill. per annum. Since MVP is
the only vaccine manufacturer In Malaysia, it Is believed that the company may capture the majority of
the market share plus some percentage of more than RM20 million-worth per annum vaccine market in
Asia.
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